A group of glaucoma specialists discuss data supporting the role of corneal hysteresis (CH)—a measure of the eye’s viscoelastic biomechanical properties—in glaucoma risk assessment. The experts give a historical perspective on CH, explain how it works as a potential biomarker, indicate which patients are good candidates and provide guidance on incorporating CH into clinical practice, highlighting important billing considerations. Importantly, they demonstrate how recent clinical research findings show compelling evidence that CH is a powerful asset for assessing patients at high risk for developing glaucoma and disease progression.